- Current report filing (8-K)
February 03 2012 - 7:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 3, 2012
|
Idenix Pharmaceuticals, Inc.
|
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-49839
|
|
45-0478605
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
60 Hampshire Street Cambridge, MA 02139
|
(Address of principal executive offices, including zip code)
Registrants telephone number, including area code: 617-995-9800
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events
On February 3, 2012, Idenix Pharmaceuticals, Inc. (the Company) issued a press release announcing that it had received
notification from the U.S. Food and Drug Administration that the partial clinical hold on IDX184 has been removed and that the Companys 12-week phase IIb study evaluating IDX184 in combination with pegylated interferon and ribavirin may
continue.
The full text of the press release is attached hereto as Exhibit 99.1. Exhibit 99.1 is incorporated by reference
into this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
|
|
|
99.1
|
|
Press Release dated February 3, 2012
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Idenix Pharmaceuticals, Inc.
|
|
|
|
|
Date: February 3, 2012
|
|
|
|
By:
|
|
/s/ Maria Stahl
|
|
|
|
|
|
|
Maria Stahl
|
|
|
|
|
|
|
Senior Vice President and General Counsel
|
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press release dated February 3, 2012
|
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about (MM) (NASDAQ): 0 recent articles
More News Articles